Patents by Inventor Hideyo HIRAI

Hideyo HIRAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-human CCR1 monoclonal antibody
    Patent number: 11912775
    Abstract: A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: February 27, 2024
    Assignees: KYOWA KIRIN CO., LTD., KYOTO UNIVERSITY
    Inventors: Masayuki Kai, Shinya Ogawa, Makoto Taketo, Kenji Kawada, Hideyo Hirai, Yoshiharu Sakai, Taira Maekawa
  • ANTI-HUMAN CCR1 MONOCLONAL ANTIBODY
    Publication number: 20240026017
    Abstract: A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Applicants: Kyowa Kirin Co., Ltd., Kyoto University
    Inventors: Masayuki Kai, Shinya Ogawa, Makoto Taketo, Kenji Kawada, Hideyo Hirai, Yoshiharu Sakai, Taira Maekawa
  • ANTI-HUMAN CCR1 MONOCLONAL ANTIBODY
    Publication number: 20200199240
    Abstract: An object of the present invention is to provide a monoclonal antibody which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The present invention relates to a monoclonal antibody which binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15), or an antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment.
    Type: Application
    Filed: July 18, 2018
    Publication date: June 25, 2020
    Applicants: KYOWA KIRIN CO., LTD., KYOTO UNIVERSITY
    Inventors: Masayuki KAI, Shinya OGAWA, Makoto TAKETO, Kenji KAWADA, Hideyo HIRAI, Yoshiharu SAKAI, Taira MAEKAWA